Pure Marrow

Pure Marrow is an early-stage biotech (founded 2020) pioneering a point-of-care cell therapy platform for hematological applications. The company's value proposition centers on providing 'clinically relevant' stem cell doses through a rapid, bedside process that avoids complex and costly manufacturing steps like culture expansion. By eliminating culture and genetic engineering, Pure Marrow aims to create a safer, faster, and potentially more accessible cell therapy product. The company is in stealth R&D mode, indicating it is refining its technology and preparing for initial clinical validation.

Bedside system for harvesting and isolating clinically relevant doses of stem cells without ex vivo culture or genetic manipulation.

Competition includes established medical device companies offering cell processing systems (e.g., Terumo BCT, Miltenyi Biotec) and biotech firms developing next-generation stem cell therapies. Pure Marrow's unique angle is the combined promise of a culture-free, bedside-ready therapeutic dose.